Cargando…

PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis

At homeostasis, a substantial proportion of Foxp3(+) T regulatory cells (T(regs)) have an activated phenotype associated with enhanced TCR signals and these effector T(reg) cells (eT(regs)) co-express elevated levels of PD-1 and CTLA-4. Short term in vivo blockade of the PD-1 or CTLA-4 pathways resu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Joseph A., Lanzar, Zachary, Clark, Joseph T., Hart, Andrew P., Douglas, Bonnie B., Shallberg, Lindsey, O’Dea, Keenan, Christian, David A., Hunter, Christopher A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028286/ https://www.ncbi.nlm.nih.gov/pubmed/36960049 http://dx.doi.org/10.3389/fimmu.2023.997376

Ejemplares similares

PD-L1 – PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection
por: Perry, Joseph A., et al.
Publicado: (2022)

IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii
por: Clark, Joseph T., et al.
Publicado: (2023)

Acute Malaria Induces PD1(+)CTLA4(+) Effector T Cells with Cell-Extrinsic Suppressor Function
por: Mackroth, Maria Sophia, et al.
Publicado: (2016)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Early T-bet promotes LFA1 upregulation required for CD8(+) effector and memory T cell development
por: Pritchard, Gretchen Harms, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
por: Dahal, Lekh N., et al.
Publicado: (2016)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4(+) T cells
por: Hao, Yuwei, et al.
Publicado: (2023)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
por: Tuccilli, Chiara, et al.
Publicado: (2018)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
por: Cai, Zongqiang, et al.
Publicado: (2021)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
por: Aghbash, Parisa Shiri, et al.
Publicado: (2021)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

Impact of secondary TCR engagement on the heterogeneity of pathogen-specific CD8(+) T cell response during acute and chronic toxoplasmosis
por: Shallberg, Lindsey A., et al.
Publicado: (2022)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Differential regulation of motility and immune synapses by CD28/ CTLA-4 costimulation in effector and regulatory T cells
por: Dilek, Nahzli, et al.
Publicado: (2012)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A
por: Cho, Hyosun, et al.
Publicado: (2016)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ph6ut8hrq5fppluremajbrasp8